HM
HealthCor Management Portfolio holdings
AUM
$109M
This Quarter Return
+32.75%
1 Year Return
+11.46%
3 Year Return
+50.01%
5 Year Return
+144.68%
10 Year Return
–
AUM
$2.77B
AUM Growth
+$270M
(+11%)
Cap. Flow
-$19.9M
Cap. Flow
% of AUM
-0.72%
Top 10 Holdings %
Top 10 Hldgs %
42.26%
Holding
73
New
19
Increased
16
Reduced
15
Closed
17
Top Buys
| 1 |
Regeneron Pharmaceuticals
REGN
|
$140M |
| 2 |
Teleflex
TFX
|
$117M |
| 3 |
Hologic
HOLX
|
$86.4M |
| 4 |
Aurinia Pharmaceuticals
AUPH
|
$80.8M |
| 5 |
Envista
NVST
|
$75.5M |
Top Sells
| 1 |
Vertex Pharmaceuticals
VRTX
|
$134M |
| 2 |
Edwards Lifesciences
EW
|
$115M |
| 3 |
Merck
MRK
|
$93.2M |
| 4 |
Baxter International
BAX
|
$90.3M |
| 5 |
Intuitive Surgical
ISRG
|
$89.7M |
Sector Composition
| 1 | Healthcare | 93.28% |
| 2 | Technology | 1.69% |
| 3 | Industrials | 0.5% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Illumina
ILMN
$15.2B
| $48.4M | 1.73% |
+149,975
| New | +$48.4M |
|
|
CHNG
27
DELISTED
Change Healthcare Inc. Common Stock
CHNG
| $46.7M | 1.67% |
2,849,650
-1,404,780
| -33% | -$23M |
|
28
IQVIA
IQV
$31.4B
| $44M | 1.57% |
284,530
+10,580
| +4% | +$1.63M |
|
29
Axsome Therapeutics
AXSM
$6.09B
| $42.2M | 1.51% |
+408,617
| New | +$42.2M |
|
|
VRAY
30
DELISTED
ViewRay, Inc.
VRAY
| $40M | 1.43% |
9,477,799
+4,587,699
| +94% | +$19.4M |
|
31
Centene
CNC
$14.8B
| $35.3M | 1.26% |
+560,900
| New | +$35.3M |
|
32
Pacira BioSciences
PCRX
$1.22B
| $34.9M | 1.25% |
+771,140
| New | +$34.9M |
|
33
Cigna
CI
$80.2B
| $34.5M | 1.23% |
+168,730
| New | +$34.5M |
|
|
AMRN
34
Amarin Corp
AMRN
$311M
| $33.5M | 1.19% |
+78,054
| New | +$33.5M |
|
35
Agios Pharmaceuticals
AGIO
$2.36B
| $33.3M | 1.19% |
+697,390
| New | +$33.3M |
|
|
ZGNX
36
DELISTED
Zogenix, Inc.
ZGNX
| $32.2M | 1.15% |
618,550
+487,560
| +372% | +$25.4M |
|
|
37
Edwards Lifesciences
EW
$47.7B
| $31.1M | 1.11% |
399,630
-1,478,340
| -79% | -$115M |
|
38
Pediatrix Medical
MD
$1.45B
| $29.9M | 1.07% |
+1,074,480
| New | +$29.9M |
|
39
Charles River Laboratories
CRL
$7.99B
| $26.7M | 0.95% |
175,000
-190,360
| -52% | -$29.1M |
|
|
BPMC
40
DELISTED
Blueprint Medicines
BPMC
| $24.7M | 0.88% |
308,538
-300,879
| -49% | -$24.1M |
|
41
Gilead Sciences
GILD
$140B
| $18.4M | 0.66% |
283,520
-199,410
| -41% | -$13M |
|
|
XLRN
42
DELISTED
Acceleron Pharma Inc.
XLRN
| $17.1M | 0.61% |
+322,540
| New | +$17.1M |
|
|
43
Vertex Pharmaceuticals
VRTX
$102B
| $14.4M | 0.51% |
65,860
-613,830
| -90% | -$134M |
|
|
HMSY
44
DELISTED
HMS Holdings Corp.
HMSY
| $13.7M | 0.49% |
+463,390
| New | +$13.7M |
|
45
Stryker
SYK
$149B
| $13.5M | 0.48% |
64,170
-22,920
| -26% | -$4.81M |
|
|
BMY.RT
46
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
| $9.46M | 0.34% |
+3,141,841
| New | +$9.46M |
|
47
Rocket Pharmaceuticals
RCKT
$358M
| $8.84M | 0.32% |
+388,360
| New | +$8.84M |
|
|
AERI
48
DELISTED
Aerie Pharmaceuticals, Inc.
AERI
| $7.31M | 0.26% |
+302,290
| New | +$7.31M |
|
49
Sarepta Therapeutics
SRPT
$1.98B
| $6.49M | 0.23% |
+50,280
| New | +$6.49M |
|
|
SRGA
50
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
| $5.92M | 0.21% |
71,955
| – | – |
|